TRACON PHARMACEUTICALS, INC.

[Available On-Demand]
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, Our lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TRC253, a small molecule inhibitor of wild type and mutated forms of the androgen receptor that has completed Phase 2 clinical development for prostate cancer, that is being developed through a collaboration with Janssen Pharmaceutica N.V.; TJ004309, a CD73 antibody that is in Phase 1 testing, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma.
Ticker:
TCON
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & CEO
Tracon Pharmaceuticals, Inc